IndraLab

Statements


| 1

reach
"Cotargeting of EGFR and USP13 led to a robust increase in treatment efficacy both in vitro and in vivo, mainly due to a strong induction of apoptosis rather than enhancing the cell cycle arrest caused by afatinib alone."